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Background: Schizophrenia and bipolar depression trials suggest that quetiapine may have an antidepressant
effect.
Objectives: This meta-analysis aimed to determine the efficacy, acceptability and tolerability of quetiapine
treatment for major depressive disorder (MDD). Only the randomized controlled trials (RCTs) comparison between
quetiapine and placebo were included. The authors searched such clinical trials carried out between 1991 and
February 2012.
Data sources: MEDLINE, EMBASE, CINHL, PsycINFO and Cochrane Controlled Trials Register were searched in
February 2012. Study populations comprised adults with MDD or major depression.
Study eligible criteria, participants and interventions: Eligible studies were randomized, placebo-controlled
trials of quetiapine monotherapy carried out in adults with MDD and presenting endpoint outcomes relevant to:
i) depression severity, ii) response rate, iii) overall discontinuation rate, or iv) discontinuation rate due to adverse
events. No language restriction was applied.
Study appraisal and synthesis methods: All abstracts identified by the electronic searches were examined. The
full reports of relevant studies were assessed, and the data of interest were extracted. Based on the Cochrane
methods of bias assessment, risks of bias were determined. The studies with two risks or less were included. The
efficacy outcomes were the mean change scores of depression rating scales, the overall response rate, and the
overall remission rates. The overall discontinuation rate was considered as a measure of acceptability. The
discontinuation rate due to adverse events was a measure of tolerability. Relative risks (RRs) and weighted mean
differences (WMDs) with 95% confidence intervals (CIs) were computed by using a random effect model.
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Results: A total of 1,497 participants in three RCTs were included. All trials examined the quetiapine
extended-release (XR). The pooled mean change scores of the Montgomery-Asberg Depression Rating Scale
(MADRS) and the Hamilton Depression Rating Scale (HAM-D) of the quetiapine-treated group were higher than
those of the placebo-treated group with the WMDs (95%CI) of -3.37 (-3.95, -2.79) and -2.46 (-3.47, -1.45),
respectively. All studies defined the response and remission as ≥ 50% reduction of the MADRS total score and the
MADRS total score of ≤8 at endpoint, respectively. The overall response and remission rates were significantly
greater in the quetiapine-treated group with RRs (95%CIs) of 1.44 (1.26, 1.64) and 1.37 (1.12, 1.68), respectively. The
pooled discontinuation rate was not significantly different between groups with an RR (95%CI) of 1.16 (0.97, 1.39).
The pooled discontinuation rate due to adverse event was greater in the quetiapine group with an RR (95%CI) of
2.90 (1.87, 4.48). With respect to sleep time, the pooled mean change Pittsburgh Sleep Quality Index (PSQI) scores
of the quetiapine-treated group was also significantly higher than that of the placebo-treated group [WMD (95%CI)
of -1.21 (-1.81, -0.61)].
Limitations: Variety of quetiapine XR doses and the small number of RCTs were key limitations of this
meta-analysis.
Conclusions: Based on the limited evidence obtained from three RCTs, quetiapine XR is effective for adult patients
with MDD. The high dropout rate due to adverse events suggests that some MDD patients may not be able to
tolerate quetiapine XR. Due to the balance of its efficacy benefit and risk of side effects, as the overall
discontinuation rate shown, the acceptability of this agent is not more than placebo. These results should be
viewed as the very preliminary one. Further studies in this area are warranted.
Implication of key findings: Quetiapine may be an alternative antidepressant. However, both risk and benefit of
this agent should be taken into account for an individual patient with MDD.Background
Major depressive disorder (MDD) is a common mental
illness with a lifetime prevalence rate of 6.7% (3.8% for
men and 7.5% for women) [1]. As a disabling, recurrent,
and chronic condition, it is a major burden for indivi-
duals, family members, communities and health care
services [2,3]. In 2000, depression was an important
cause of disease burden accounting for 4.4% of the total
disability adjusted life years or 12% of all total years lived
with disability worldwide [4].
Common classes of agents for the treatment of MDD in-
clude selective serotonin reuptake inhibitors (SSRIs) [5,6],
serotonin-norepinephrine reuptake inhibitors (SNRIs) [7,8],
tricyclic antidepressants (TCAs) [9-11] and monoamine
oxidase inhibitors (MAOIs) [12]. Several meta-analytic find-
ings suggest that patients with MDD may not fully respond
and/or do not fully remit after receiving adequate doses
and duration of these antidepressants. Only 30%-55% of
MDD patients achieve remission state at the end of acute
SSRI or SNRI treatment [13,14]. In addition, the overall
dropout rates and the dropout rates due to adverse events
are relatively high in the ranges of 25-39% and 9-17%
[15,16], respectively, which suggest that many MDD
patients cannot accept or tolerate currently available antide-
pressants [17]. While these antidepressants presumably
affect serotonin and norepinephrine neurotransmitters, sev-
eral lines of evidence support that dopamine neurotrans-
mitters may also play an important role in the treatment of
MDD patients [18,19].Quetiapine and its mainly active metabolite, N-
desalkylquetiapine (norquetiapine), have various pharmaco-
logical effects on central serotonergic and dopaminergic
receptors, which presumably involve in its efficacy for the
treatment of schizophrenia [20]. Recently, norquetiapine
has been found to be a potent inhibitor for norepinephrine
transporter shared commonality with TCAs and SNRIs,
and a moderate-to-high affinity for D2, 5HT1A, 5HT2A,
and 5HT2C receptors shared some properties with SSRIs
[20,21]. These mechanisms of action may explain its effi-
cacy for the treatment of depression and anxiety [21-24].
Several lines of research suggest that quetiapine may
have an antidepressant effect. Some clinical trials found
that quetiapine reduced depressive symptoms consi-
derably in schizophrenic patients [25] and bipolar
depression [26,27]. Although some experts view that its
antidepressant effect may not be superior to other anti-
depressants [28], this is the only agent approved for the
treatment of acute bipolar depression [29].
Recently, some randomized-controlled trials of quetia-
pine have been conducted in patients with MDD
[30-33]. Since most of these studies have small samples,
a meta-analysis, which is more powerful in estimating
the true effect size, may be a strategy to confirm its
efficacy and safety.
To determine the efficacy, acceptability and tolerability
of quetiapine monotherapy in patients with MDD, we
conducted a systematic review of randomized, placebo-
controlled trials of quetiapine in these patients.
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The authors searched such clinical trials carried out
between 1991 and February 2012.Eligibility criteria
The included studies were randomized, placebo-
controlled trials of quetiapine monotherapy in adults
(18–65 years old) with MDD. Depressive severity was
rated at baseline and during treatment with standard rat-
ing scales [34] and reported the response rate, the over-
all discontinuation rate or the discontinuation rate due
to adverse events were included. Studies with any dur-
ation of treatment for single or recurrent major depressive
episodes diagnosed by any set of criteria were included. No
language restriction was applied.Information sources
We searched MEDLINE, EMBASE, CINHL, PsycINFO
and Cochrane Controlled Trials Register databases in
February 2012. According to MEDLINE search, the first
publication of the ICI 204,636 (the drug code of quetia-
pine) was in 1991. The searches, therefore, covered the
period of 1991- February 2012. Searches were limited to
humans and adults only. Additional studies were also
searched from the databases of AstraZeneca, the produ-
cer of the original quetiapine. References of the articles
obtained by any means were searched. All relevant
randomized-controlled trials (RCTs) and clinical-controlled
trials (CCTs) were included.Searches
The MEDLINE search strategies for optimal sensitivity in
identifying randomized clinical trials used the following
words and phrases: [(quetiapine) OR (seroquel)] AND
[(major depressive disorder) OR (MDD) OR (major
depression) OR (severe depressive episode)]. Similarly,
these search strategies were used in the rest of databases.Study selection
Two reviewers (NM and BM) independently examined
all abstracts identified by electronic searches to deter-
mine those meeting the eligible studies described above.
The full-text articles of relevant studies were obtained.
The reviewers then independently assessed all full study
reports. Disputes were resolved through consensus.Data collection process
We developed a data extraction form. A reviewer (NM)
extracted the data into the form. The second reviewer
(BM) checked the extracted data. Any disputes between
reviewers were resolved by consensus. If no agreement
could be reached, the third author (MS) would decide.Data items
Extracted data obtained from each trial included: (1)
study details needed for validity assessment; (2) baseline
characteristics of participants, diagnostic criteria, study
design and inclusion/exclusion criteria; (3) form, dose,
and duration of quetiapine compared to placebo; (4) out-
comes of interest. As far as possible, the intention-to
treat results were recorded.
Risk of bias in individual studies
Two reviewers (NM and BM) rated the internal validity
(quality) of each eligible randomized trial. Based on the
Cochrane Collaboration quality assessment for trials, risks
of bias were determined by: 1) the quality of randomization,
2) concealment of allocation, 3) blinding, 4) baseline simi-
larity, 5) intention-to-treat analysis, 6) free of selective
reporting, and 7) free of other biases [35]. Studies with two
risks or less were included in the analysis.
Summary measures
Outcomes of interest included efficacy, acceptability and
tolerability. Efficacy measures relied on the mean change
scores of a rating scale for MDD and the response rates
defined by any set of criteria. Since acceptability and toler-
ability have been used interchangeably, both terms were
specifically defined. Similar to a previous meta-analysis, the
acceptability in this review was derived from the overall
discontinuation rate [17]. The tolerability, frequently
defined as a measure of antidepressant side effects [36],
was drawn from the discontinuation rate due to adverse
events.
Relative risks (RRs), the ratios of the probability of the
event occurring in the experimental (intervention) group
versus the controlled group, with the 95% confidence
interval (95%CI) were used for synthesizing the dichot-
omous data. A relative risk of one indicates no difference
between comparison groups. For an unwanted outcome,
an RR lesser than one suggests the less likelihood of the
occurrence of such outcome. In this meta-analysis, rela-
tive risks were used to compare the response rates, over-
all discontinuation rates, and discontinuation rates due
to adverse events between groups. In addition to the
measure of efficacy, the number needed to treat (NNT),
the number of patients who must receive a particular
therapy for one to benefit, was also calculated.
A weighted or standardized mean difference (WMD or
SMD) is the difference between two means divided by
an estimate of the within group standard deviation; this
mean difference, with 95%CI, was used for the synthesis
of continuous data. When an outcome is measured by
different instruments across studies, it may not be pos-
sible to compare or combine study results directly. By
expressing the effect as a standardized value, the results
can be combined since they have no unit. As a function
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plausible when the same instrument of measurement
was used. In the present review, the WMDs or the
SMDs were planned to be calculated if the retrieved
studies used the same rating scale or different rating
scales, respectively. When a standard deviation (SD) for
mean change of depressive rating score was not pro-
vided, we estimated the SD by using direct substitution
or any statistical method [37].
Synthesis of results
Both fixed effect and random effect models can be used
for data synthesis. For the fixed effect approach, we as-
sume that all included studies share a common effect
size. The ignorance of this between-study variation is
also the main difference from a random effect model.
For most instances, the assumption of one true effect
size may be implausible. Although the included studies
are relatively similar, there is generally no reason to as-
sume that they are exactly the same. For this reason, a
random effect model was applied for the synthesis of
























































Figure 1 Flow diagram of study * http://www.astrazenecaclinicaltrialsRisk of bias across studies
To detect the reporting biases, a funnel plot, a simple
plot of the intervention effect estimating from individual
studies against some measure of each study’s size or pre-
cision [38], was applied.Test of heterogeneity
A test of heterogeneity is necessary for evaluating the
similarity of the study results. Before conducting this
meta-analysis, we hypothesized that the effect size
may differ due to the methodological quality of the
studies. We checked whether the study results had
greater differences than expected by chance alone.
This was done by observing the results presented by
graphical display and using the test of heterogeneity.
An I2 of 50% or higher was considered as significant
heterogeneity of results.Statistical software
All analyses were conducted using the RevMan 5.1 (The
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150 and 300 mg/
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MADRS, HAM-D, HAM-A, CGI-S, CGI-I,




700 18–65 8 Quetiapine XR/
50, 150 and 300
mg/day





MADRS, HAM-D, HAM-A, CGI-S, CGI-I,




299 18–65 10 Quetiapine XR/
150 to 300 mg/
day





MADRS, HAM-D, HAM-A, CGI-S, CGI-I,
PSQI, SAS, BARS, CSFQ, Q-LES-Q, 18-
item TDSS scale
MADRS = Montgomery-Åsberg Depression Rating Scale; HAM-D = Hamilton Rating Scale for Depression; HAM-A = Hamilton Rating Scale for Anxiety; CGI-S=
Clinical Global Impression–Severity of Illness; CGI-I = Clinical Global Impression–Improvement scale; PSQI = Pittsburgh Sleep Quality Index; SAS = Simpson-Angus
Scale, BARS = Barnes Akathisia Rating Scale; CSFQ = Changes in Sexual Functioning Questionnaire; Q-LES-Q = Quality of Life Enjoyment Satisfaction Questionnaire;
TDSS scale = Treatment discontinuation.
Table 2 Risk of bias summary of controlled trials of
quetiapine in major depressive disorder
Study Issues of bias
1 2 3 4 5 6 7 8
Cutler AJ 2009 N N N N N N N N
Weisler R 2009 N N N N N N N N
Bortnick B 2011 N/A N/A N N N N N N
1=Adequate sequence generation; 2 = Allocation concealment; 3=Blinding
(Subjective outcome); 4 = Dropout data addressed; 5 = Free of selective
reporting; 6 = Free of other bias; 7 = Baseline similarity; 8 = Intention-to-treat
analysis or modified intention-to-treat analysis; N/A = not available; N = No
risk of bias.
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Study selection
Database searches provided a total of 168 citations
(Medline = 15 studies, EMBASE= 34 studies, CINHL=4
studies, PsycINFO= 101 studies, Cochrane Controlled
Trials Register = 0 study and Astra Zeneca Clinical
Trials = 14) (see Figure 1). After the remove of dupli-
cates, 141 trials remained. By reviewing the titles
and abstracts, 136 trials were excluded since they
clearly did not meet the criteria. Full papers of five
studies were examined [30-33,39], two studies were
excluded since one was a study of maintenance
treatment [30] and the other studied in geriatric
patients [39], only three trials [31-33], therefore,
were included in the review. No relevant, unpub-
lished study meeting the inclusion criteria was
identified.
Study characteristics
The study periods of the three trials ranged from 8 to 11
weeks. All studies had wash-out periods (up to 4 weeks)
for discontinuing psychotropic medications followed by
randomization and a 2-week, post-treatment, drug-
discontinuation phase.
Of 1,497 participants, 64.3% were female. All parti-
cipants were outpatients with MDD, single or recur-
rent episode. None of them had treatment-resistant
depression. Mean ages of the quetiapine and placebo
groups were 41.38 (SD = 11.68) and 41.66 (SD = 11.72),
respectively. The patients in all studies were treated
with the extended-release (XR) form of quetiapine.
The dosage of quetiapine XR ranged from 50 to
300 mg/day. Table 1 shows the main characteristics
of included studies.
Since all three studies reported mean change scores of
Montgomery-Asberg Depression Rating Scale (MARDS)
and Hamilton Depression Rating Scale (HAM-D), the
WMDs of mean change scores were calculated andsynthesized. Remission rate, response rates, overall discon-
tinuation rates, and discontinuation due to adverse events
were also reported in all studies.
Risk of bias within studies
All studies applied the technique of randomization,
double-blind placebo control, and modified intention-to
treat analysis. Dropout data and baseline similarity were
reported in all studies. Only two studies [32,33] reported
sequence generation of randomization and allocation
concealment. No risk of bias for baseline similarity and
other bias were found (see Table 2). As all studies had
low risks of bias, the data of all three trials were
included in the analysis.
Results of individual studies
The response rate of the quetiapine-treated group in
each study was significantly greater than that of the
placebo-treated group (see Figure 2). However, the
remission rate of the quetiapine-treated group in each
study was not significantly higher than that of the
placebo-treated group (see Figure 3). The mean change
MADRS and HAM-D scores of the quetiapine-treated
group in each study were higher than that of the
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Figure 2 Comparison of relative risk (95% confidence interval) for clinical response rates in patients with MDD: quetiapine vs. placebo.
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Efficacy
No significant heterogeneity was found on all efficacy
outcomes, except HAM-D scores. The pooled response
rate of the quetiapine -treated group was significantly
greater than that of the placebo-treated group [RR (95%
CI) of 1.44 (1.26, 1.64), I2 = 0%] (see Figure 2). The
pooled remission rate of the quetiapine-treated group
was also significantly greater than that of the placebo-
treated group [RR (95%CI) of 1.37 (1.12, 1.68), I2 = 0%]
(see Figure 3). The pooled mean change MADRS score
of the quetiapine-treated group was significantly higher
than that of the placebo-treated group [WMD (95%CI)
of -3.37 (-3.95, -2.79), I2 = 0%] (see Figure 4). The pooled
mean change HAM-D score of the quetiapine-treated
group was also significantly higher than that of the
placebo-treated group [WMD (95%CI) of -2.46 (-3.47,
-1.45), I2 = 89%] (see Figure 5). With respect to sleep
time, the pooled mean change Pittsburgh Sleep Quality
Index (PSQI) score of the quetiapine-treated group was
also significantly higher than that of the placebo-treated
group [WMD (95%CI) of -1.21 (-1.81, -0.61), I2 = 48%].
According to the pooled response rate obtained from all
trials, the NNT (95%CI) was 7.2 (5.2-11.7).
Discontinuation rates
There was no significant heterogeneity on both discon-
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Figure 3 Comparison of relative risk (95% confidence interval) for clin
placebo.rate of the quetiapine group was not significantly differ-
ent from that of the placebo group [RR (95%CI) of 1.16
(0.97, 1.39), I2 = 0%]. However, the pooled discontinu-
ation rate due to adverse events in the quetiapine group
was significantly higher than that of the placebo group
[RR (95%CI) of 2.90 (1.87, 4.48), I2 = 0%].Risk of bias across studies
Tests for funnel plot asymmetry is normally used in the
meta-analysis with at least 10 studies included; the
power of the tests is too low to distinguish chance from
real asymmetry, if fewer studies [38]. Because only 3
studies were included in this analysis, a test for funnel
plot, therefore, was not done.Discussion
Our review found only three randomized, placebo-
controlled trials of quetiapine carried out in adult patients
with MDD. All studies had the same study designs. The
preliminary findings of this meta-analysis suggest that
quetiapine monotherapy is effective for adult patients with
MDD. Based on the pooled response rates, the NNT of
7.2 indicates that, by average, every 1 in 8 patients with
MDD will respond to quetiapine treatment. The high
dropout rate due to adverse events suggests that some
MDD patients may not be able to tolerate quetiapine XR.
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IV, Random, 95% CI
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Figure 4 Comparison the mean changes from baseline of MADRS (95% confidence interval) in patients with MDD: quetiapine vs.
placebo.
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ceptability of this agent is not more than placebo.
In this review, the pooled response rate for quetiapine
monotherapy in MDD patients (51.51%) was superior to
placebo (37.55%). Similarly, a meta-analysis of 7 RCTs
found that the response rates of bupropion and SSRIs
treatment in MDD patients were 62 and 63%, respect-
ively, compared with 51% for placebo [40]. The remis-
sion rate of quetiapine treatment (27.31%) is also greater
than that of placebo one (21.16%). Previous meta-
analyses found that the remission rates of TCAs, SSRIs,
and SNRIs were 44.1, 37.7 and 31-55% respectively [41].
It should be noted that not only the response and remis-
sion rates of quetiapine treatment but also those of pla-
cebo treatment found in this study were lower than
previous findings. Therefore, the cross-trial comparisons
of the response and remission rates of quetiapine with
those of other antidepressants may not be justified.
Absolute risk reduction (ARR) is the difference be-
tween the control group’s event rate and the experi-
mental group’s event rate. As a measure of the size of
difference between two treatments (e.g., antidepressants
and placebo), the ARR may be a logical method for com-
paring the remission and response rates of antidepres-
sants across studies. Based on the ARR, quetiapine
increases the response rate for 13.96% (51.51% for
quetiapine group vs. 37.55% for placebo group), while
bupropion and SSRIs increase the response rates for
11% and 12%, respectively (62% for bupropion group
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Figure 5 Comparison the mean changes from baseline of HAM-D (95
placebo.Regarding the response rates of other antidepressants in
adults with MDD, the NNTs of fluoxetine and venlafax-
ine are between 5 and 7, which are comparable to the
NNT of 8 for the quetiapine treatment in this popula-
tion [42]. Not surprisingly, as an inverse of the ARR, the
comparable of ARRs between quetiapine and other anti-
depressants, the NNTs of these agents are, therefore,
comparable. However, the ARR for the remission rate of
quetiapine treatment [6.15% (27.31% for quetiapine vs.
21.16% for placebo)] is relatively lower than those of
SSRIs and bupropion [11% (47% for SSRIs and bupro-
pion vs. 36% for placebo)] [40]. It is not yet known
whether these differences reflect the true lower remis-
sion rate of quetiapine treatment or only the dissimilar-
ity of participants and study designs among the studies.
Similar to other antidepressants, the acceptability of
quetiapine for the treatment of MDD is not higher than
that of placebo. The nonsignificant differences in this re-
spect have been found in a number of meta-analyses of
paroxetine [43] and duloxetine [44] and TCAs [10] for
the treatment of MDD. The low tolerability of quetia-
pine treatment for MDD is also similar to previous find-
ings of other antidepressants, e.g. TCAs [45], SSRIs [45]
and SNRIs [46,47]. These lines of evidence suggest that
almost all antidepressants, including quetiapine, have
the same profile of comparable acceptability to and less
tolerability than placebo.
Sleep disturbance is common in MDD and may com-
plicate its treatment. Up to 31% of MDD patients may
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and SNRIs [50]. The findings of sleep quality improved
by quetiapine suggests an advantage of quetiapine for
the treatment of MDD.
There were several limitations of this review. Firstly,
the doses of quetiapine were different across the
included studies. While a study used a flexible dose with
titration, the others applied fixed and multiple doses in
several arms. Secondly, this meta-analysis included only
three RCTs sponsored by a pharmaceutical company
holding the patent of quetiapine XR. These results,
therefore, should be viewed as the very preliminary find-
ings. Thirdly, although all studies adhered to the same
methods of double blindness/randomization, had similar
baseline characteristics, and applied the intention-to-
treat analysis or modified intention-to-treat analysis for
the data analyses, 1 of 3 studies did not report an
adequate sequence generation of randomization and
the allocation concealment. Fourthly, as with all meta-
analyses, publication bias must be considered. However,
due to the small number of included studies, we did not
assess the possibility of publication bias [38].
Conclusions
Based on the limited evidence obtained from three
RCTs, quetiapine XR is effective for adult patients with
MDD. The high dropout rate due to adverse events sug-
gests that some MDD patients may not be able to toler-
ate quetiapine XR. Due to the balance of its efficacy
benefit and risk of side effects, as the overall discontinu-
ation rate shown, the acceptability of this agent is not
more than placebo. These results should be viewed as
the very preliminary one. Further studies in this area are
warranted.
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